Johnson & Johnson was the top cybersecurity innovator in the clinical trial operations sector in the last quarter. The company filed 45 related patents in the three months ending November in 2021. Although, that was down from 111 over the same period in 2020.
J&J was followed by Novartis with 22 patent applications, Roche (21 applications), and Bristol Myers Squibb (20 applications).
BMS has recently ramped up R&D in cybersecurity. It saw growth of 60% in related patent applications in the three months ending November compared to the same period in 2020 - the highest percentage growth out of all companies tracked with more than 10 quarterly patents in the clinical trial operations sector.
Nevertheless, research and innovation in cybersecurity in the clinical trial operations sector has declined in the last year.
The most recent figures show that the number of patent applications in the industry stood at 112 in the three months ending November - down from 188 over the same period in 2020.
Figures for patent grants related to followed a similar pattern to filings - shrinking from 163 in the three months ending November in 2020 to 109 this year.
The figures are compiled by GlobalData, who track patent filings and grants from official offices around the world. Using textual analysis, as well as official patent classifications, these patents are grouped into key thematic areas, and linked to key companies across various industries.
is one of the key areas tracked by GlobalData. It has been identified as being a key disruptive force facing companies in the coming years, and is one of the areas that companies investing resources in now are expected to reap rewards from.
The figures also provide an insight into the largest innovators in the sector.